首页> 外文期刊>The Lancet >Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study.
【24h】

Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study.

机译:预防性复方新诺明,抗逆转录病毒疗法和杀虫剂处理的蚊帐对乌干达HIV-1感染的成年人疟疾发生频率的影响:一项前瞻性队列研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: HIV-1 and malaria are common infections in Africa, and cause substantial morbidity and mortality. HIV infection has been associated with an increased incidence of malaria, and more severe disease. Our aim was to assess the effect of antiretroviral treatment (ART) on the frequency of clinical malaria in people with HIV, and to measure the additive effects of co-trimoxazole (trimethoprim and sulfamethoxazole) prophylaxis, ART, and insecticide-treated bednets. METHODS: In 2001, we enrolled 466 HIV-infected individuals aged 18 years or older in Uganda in a prospective cohort study that provided co-trimoxazole prophylaxis to 399 participants after 5 months of no intervention. In 2003, we enrolled 138 survivors from the initial study, and 897 new participants from the same community, to take antiretroviral therapy (ART) in addition to co-trimoxazole prophylaxis. The ART was in most cases a combination of stavudine, lamivudine, and nevirapine or efavirenz. In 2004, we also gave participants insecticide-treated bednets. Households were visited weekly by study staff to record fever, illness, or death in the preceding 7 days. In cases of reported fever in the previous 2 days, we took blood to test for malaria parasites. We compared the frequency of clinical malaria, adjusting for CD4-cell count, age, sex, and season. FINDINGS: 1035 individuals were given co-trimoxazole and ART (median age 38 years, 74% female, and median CD4-cell count 124 cells/microL); 985 of these, plus four new participants, received co-trimoxazole, ART, and bednets. There were 166 cases of clinical malaria in the study. Compared with a baseline malaria incidence of 50.8 episodes per 100 person-years, co-trimoxazole prophylaxis was associated with 9.0 episodes per 100 person-years (adjusted incidence rate ratio [IRR] 0.24, 95% CI 0.15-0.38); ART and co-trimoxazole with 3.5 episodes per 100 person-years (0.08, 0.04-0.17); and co-trimoxazole, ART, and bednets with 2.1 episodes per 100 person-years (0.05, 0.03-0.08). Malaria incidence was significantly lower during ART and co-trimoxazole than during co-trimoxazole alone (IRR 0.36 [95% CI 0.18-0.74], p=0.0056). INTERPRETATION: A combination of co-trimoxazole, antiretroviral therapy, and insecticide-treated bednets substantially reduced the frequency of malaria in adults with HIV.
机译:背景:HIV-1和疟疾是非洲的常见感染,并导致大量发病和死亡。 HIV感染与疟疾发病率增加和更严重的疾病有关。我们的目标是评估抗逆转录病毒治疗(ART)对HIV感染者的临床疟疾发生率的影响,并评估预防用药复方新诺明(trimethoprim和sulfamethoxazole),ART和经杀虫剂处理的蚊帐的累加作用。方法:2001年,我们在一项前瞻性队列研究中招募了466名年龄在18岁或18岁以上的HIV感染者,该研究在5个月没有干预的情况下为399名参与者提供了预防性的复方新诺明治疗。 2003年,我们从初始研究中招募了138名幸存者,并从同一社区招募了897名新参与者,以预防复方新诺明的同时接受抗逆转录病毒疗法(ART)。在大多数情况下,抗病毒治疗是司他夫定,拉米夫定和奈韦拉平或依非韦伦的组合。 2004年,我们还为参与者提供了经过杀虫剂处理的蚊帐。研究人员每周都要对住户进行访问,以记录前7天的发烧,疾病或死亡情况。如果在前两天有发烧的报道,我们会抽血检查疟疾寄生虫。我们比较了临床疟疾的发生频率,并调整了CD4细胞计数,年龄,性别和季节。结果:1035例患者接受了复方新诺明和抗逆转录病毒治疗(中位年龄38岁,女性74%,中位CD4细胞计数为124个细胞/微升);其中的985位,加上四个新的参与者,接受了复方新诺明,抗逆转录病毒疗法和蚊帐。该研究中有166例临床疟疾病例。与每100人年50.8次发作的基线疟疾发病率相比,预防性使用三甲唑的预防与每100人年9.0次发作相关(调整后发生率[IRR] 0.24,95%CI 0.15-0.38);每100人年有3.5次发作的ART和复方新诺明(0.08,0.04-0.17);每100人年2.1次发作(0.05,0.03-0.08)。在抗逆转录病毒治疗和联合曲莫唑期间,疟疾发病率明显低于单独使用曲莫唑期间(IRR 0.36 [95%CI 0.18-0.74],p = 0.0056)。解释:复方新诺明,抗逆转录病毒疗法和经杀虫剂处理过的蚊帐的结合,大大降低了成人HIV感染者的疟疾发病率。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号